Chan, Irenaeus C. C.
Zhang, Pu
Pan, Xiangyu https://orcid.org/0000-0002-2537-6616
Castro, Cynthia
Fox, Nina https://orcid.org/0009-0008-3346-9995
Lewis, Alexander M. https://orcid.org/0000-0001-8003-9535
Weis, Kenyon
Cuibus, Adriana https://orcid.org/0009-0006-9660-239X
Tittley, Steven
Petrone, Giulia https://orcid.org/0000-0003-3166-4355
Beeler, J. Scott https://orcid.org/0000-0002-1829-1972
Tran, Duc https://orcid.org/0000-0003-2918-8601
Mustion, Griffen https://orcid.org/0009-0005-5505-5775
Fronick, Catrina https://orcid.org/0000-0002-2766-9551
Stopsack, Konrad H. https://orcid.org/0000-0002-0722-1311
Cruchaga, Carlos https://orcid.org/0000-0002-0276-2899
Abdel-Wahab, Omar https://orcid.org/0000-0002-3907-6171
Bolton, Kelly L. https://orcid.org/0000-0001-6584-3357
Funding for this research was provided by:
Damon Runyon Cancer Research Foundation
Edward P. Evans Foundation
V Foundation for Cancer Research
U.S. Department of Health & Human Services | NIH | National Institute on Aging (R01AG088690-01)
U.S. Department of Health & Human Services | National Institutes of Health (R01 CA251138)
U.S. Department of Health & Human Services | National Institutes of Health (CA283364)
U.S. Department of Health & Human Services | National Institutes of Health (CA242020)
U.S. Department of Health & Human Services | National Institutes of Health (HL128239)
U.S. Department of Health & Human Services | National Institutes of Health (P50 CA254838-01)
U.S. Department of Health & Human Services | National Institutes of Health (P30 CA08748)
Neil S. Hirsch Foundation, Jonas Family, and BreakThrough Cancer
American Society of Hematology
Article History
Received: 9 September 2025
Accepted: 27 January 2026
First Online: 11 March 2026
Competing interests
: K.L.B. receives research funding and serves on the medical advisory board of Servier Pharmaceuticals. O.A.-W. is a founder of and scientific advisor to Codify Therapeutics, holds equity in the company and receives research funding from it; has served as a consultant for Amphista Therapeutics, MagnetBio and AstraZeneca; serves on the scientific advisory boards of Envisagenics, Harmonic Discovery and Pfizer Boulder; and has received prior research funding from Nurix Therapeutics and Minovia Therapeutics unrelated to the current study. The remaining authors declare no competing interests.